Acinetobacter baumannii-a member of the ESKAPE group-has been classified by the World Health Organization as a Priority 1 "critical" pathogen because of its formidable resistance to last-line antibiotics such as carbapenems and colistin. Identifying alternative therapeutics is therefore imperative, and natural product molecules are getting attention in this field. This study surveyed bioactive metabolites from Boerhavia diffusa and evaluated their affinity for GMP synthase (guaA), an enzyme essential for bacterial guanine nucleotide biosynthesis, by several AI-guided in silico approaches. A homology-modelled, energy-minimised 3D structure of guaA displayed sound stereochemistry, validating it as a docking target. Medicinal-chemistry profiling of a focused phytochemical library highlighted five Boeravinone derivatives-Boeravinones G (L1), F (L2), A (L3), B (L4), and I (L5)-that met stringent drug-likeness, ADME, and toxicity criteria. All five compounds docked to guaA with stronger binding energies (-7.6 to -8.4 kcal/mol) and richer hydrogen-bond networks than imipenem's interaction with its native penicillin-binding protein (-6.3 kcal/mol). L3 and L5 were the top performers, posting binding energies of -8.4 and -8.0 kcal/mol, respectively. One-hundred-nanosecond molecular-dynamics simulations confirmed complex stability, as evidenced by consistent RMSD, RMSF, and SASA trajectories, as well as favourable FEL and DCCM maps. MM/GBSA and MM/PBSA calculations further underscored thermodynamic viability: guaA-L3 and guaA-L5 complexes exhibited ΔGbind values of -56.8 ± 28.1 and -62.1 ± 15.4 kcal/mol, respectively, outperforming other candidates. Collectively, these data nominate Boeravinone derivatives-particularly L3 and L5-as promising guaA inhibitors and furnish a computational blueprint for developing novel agents against multidrug-resistant A. baumannii.